Gilead Sciences Inc Net Assets
Gilead Sciences Inc net assets. Based on the latest financial reports, Gilead Sciences Inc (GILD) has net assets worth $11.74 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($49.36 Billion) and total liabilities ($37.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Gilead Sciences Inc net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.74 Billion |
| % of Total Assets | 23.79% |
| Annual Growth Rate | 24.62% |
| 5-Year Change | 7.38% |
| 10-Year Change | 16.81% |
| Growth Volatility | 155.74 |
Net Assets of Gilead Sciences Inc (1990–2025)
Net assets of Gilead Sciences Inc from 1990 to 2025. This chart illustrates how Gilead Sciences Inc's net assets have evolved over time, based on quarterly financial data. See Gilead Sciences Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Gilead Sciences Inc (1990–2025)
The table below shows the annual net assets of Gilead Sciences Inc from 1990 to 2025. For live market cap and overall valuation, see GILD market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $22.62 Billion | +17.52% |
| 2024-12-31 | $19.25 Billion | -15.40% |
| 2023-12-31 | $22.75 Billion | +7.26% |
| 2022-12-31 | $21.21 Billion | +0.69% |
| 2021-12-31 | $21.06 Billion | +15.60% |
| 2020-12-31 | $18.22 Billion | -19.55% |
| 2019-12-31 | $22.65 Billion | +5.18% |
| 2018-12-31 | $21.53 Billion | +5.04% |
| 2017-12-31 | $20.50 Billion | +5.88% |
| 2016-12-31 | $19.36 Billion | +1.31% |
| 2015-12-31 | $19.11 Billion | +20.82% |
| 2014-12-31 | $15.82 Billion | +34.69% |
| 2013-12-31 | $11.74 Billion | +23.07% |
| 2012-12-31 | $9.54 Billion | +38.97% |
| 2011-12-31 | $6.87 Billion | +12.18% |
| 2010-12-31 | $6.12 Billion | -5.89% |
| 2009-12-31 | $6.51 Billion | +45.67% |
| 2008-12-31 | $4.47 Billion | +24.03% |
| 2007-12-31 | $3.60 Billion | +92.65% |
| 2006-12-31 | $1.87 Billion | -38.28% |
| 2005-12-31 | $3.03 Billion | +61.84% |
| 2004-12-31 | $1.87 Billion | +86.53% |
| 2003-12-31 | $1.00 Billion | +75.55% |
| 2002-12-31 | $571.34 Million | +26.28% |
| 2001-12-31 | $452.44 Million | +28.85% |
| 2000-12-31 | $351.12 Million | +18.11% |
| 1999-12-31 | $297.29 Million | -10.91% |
| 1998-12-31 | $333.70 Million | +5.17% |
| 1997-12-31 | $317.30 Million | +8.78% |
| 1996-12-31 | $291.70 Million | +92.54% |
| 1995-12-31 | $151.50 Million | +75.96% |
| 1994-12-31 | $86.10 Million | -25.33% |
| 1993-12-31 | $115.30 Million | -17.29% |
| 1992-12-31 | $139.40 Million | +32.01% |
| 1991-12-31 | $105.60 Million | +935.29% |
| 1990-12-31 | $10.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gilead Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1373980000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Gilead Sciences Inc Net Assets Breakdown (December 2025)
Gilead Sciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $13.73 Billion | 60.48% |
| Common Stock | $1.00 Million | 0.00% |
| Other Comprehensive Income | $39.00 Million | 0.17% |
| Other Components | $8.93 Billion | 39.34% |
| Total Equity | $22.70 Billion | 100.00% |
Gilead Sciences Inc Competitors by Market Cap
The table below lists competitors of Gilead Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IND.D.D.TEXT.UNSP.ADR 1/2
F:IXD2
|
$183.19 Billion |
|
Toyota Motor Corporation
F:TOM
|
$183.54 Billion |
|
Walt Disney Company
NYSE:DIS
|
$184.79 Billion |
|
MediaTek Inc
TW:2454
|
$184.80 Billion |
|
Toyota Motor Corporation
F:TOMA
|
$180.58 Billion |
|
Reliance Industries Limited
LSE:RIGD
|
$180.32 Billion |
|
SIEMENS AG SP. ADR 1/ 1/2
F:SIEB
|
$177.31 Billion |
|
COMMONW.BK AUSTR.SP.ADRS
F:CWW0
|
$177.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gilead Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,330,000,000 to 22,702,000,000, a change of 3,372,000,000 (17.4%).
- Net income of 8,510,000,000 contributed positively to equity growth.
- Dividend payments of 4,003,000,000 reduced retained earnings.
- Share repurchases of 1,922,000,000 reduced equity.
- New share issuances of 408,000,000 increased equity.
- Other comprehensive income decreased equity by 93,000,000.
- Other factors increased equity by 472,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.51 Billion | +37.49% |
| Dividends Paid | $4.00 Billion | -17.63% |
| Share Repurchases | $1.92 Billion | -8.47% |
| Share Issuances | $408.00 Million | +1.8% |
| Other Comprehensive Income | $-93.00 Million | -0.41% |
| Other Changes | $472.00 Million | +2.08% |
| Total Change | $- | 17.44% |
Book Value vs Market Value Analysis
This analysis compares Gilead Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5003.77x to 9.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.03 | $167.47 | x |
| 1991-12-31 | $0.29 | $167.47 | x |
| 1992-12-31 | $0.27 | $167.47 | x |
| 1993-12-31 | $0.19 | $167.47 | x |
| 1994-12-31 | $0.14 | $167.47 | x |
| 1995-12-31 | $0.22 | $167.47 | x |
| 1996-12-31 | $0.33 | $167.47 | x |
| 1997-12-31 | $0.31 | $167.47 | x |
| 1998-12-31 | $0.25 | $167.47 | x |
| 1999-12-31 | $0.22 | $167.47 | x |
| 2000-12-31 | $0.24 | $167.47 | x |
| 2001-12-31 | $0.28 | $167.47 | x |
| 2002-12-31 | $0.35 | $167.47 | x |
| 2003-12-31 | $0.62 | $167.47 | x |
| 2004-12-31 | $1.01 | $167.47 | x |
| 2005-12-31 | $1.60 | $167.47 | x |
| 2006-12-31 | $0.99 | $167.47 | x |
| 2007-12-31 | $1.79 | $167.47 | x |
| 2008-12-31 | $2.23 | $167.47 | x |
| 2009-12-31 | $3.41 | $167.47 | x |
| 2010-12-31 | $3.36 | $167.47 | x |
| 2011-12-31 | $4.26 | $167.47 | x |
| 2012-12-31 | $5.88 | $167.47 | x |
| 2013-12-31 | $6.71 | $167.47 | x |
| 2014-12-31 | $9.60 | $167.47 | x |
| 2015-12-31 | $12.57 | $167.47 | x |
| 2016-12-31 | $14.26 | $167.47 | x |
| 2017-12-31 | $15.50 | $167.47 | x |
| 2018-12-31 | $16.35 | $167.47 | x |
| 2019-12-31 | $17.64 | $167.47 | x |
| 2020-12-31 | $14.41 | $167.47 | x |
| 2021-12-31 | $16.69 | $167.47 | x |
| 2022-12-31 | $16.83 | $167.47 | x |
| 2023-12-31 | $18.15 | $167.47 | x |
| 2024-12-31 | $15.40 | $167.47 | x |
| 2025-12-31 | $18.09 | $167.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gilead Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 37.49%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.90%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 2.60x
- Recent ROE (37.49%) is above the historical average (13.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -39.22% | -307.69% | 0.10x | 1.23x | $-5.02 Million |
| 1991 | -4.26% | -160.71% | 0.03x | 1.03x | $-15.06 Million |
| 1992 | -10.11% | -335.71% | 0.03x | 1.05x | $-28.04 Million |
| 1993 | -22.29% | -626.83% | 0.03x | 1.10x | $-37.23 Million |
| 1994 | -36.35% | -638.78% | 0.05x | 1.19x | $-39.91 Million |
| 1995 | -18.09% | -1014.81% | 0.02x | 1.10x | $-42.55 Million |
| 1996 | -7.44% | -64.97% | 0.11x | 1.07x | $-50.87 Million |
| 1997 | -22.98% | -55.10% | 0.38x | 1.11x | $-104.63 Million |
| 1998 | -13.43% | -29.65% | 0.31x | 1.46x | $-78.17 Million |
| 1999 | -22.37% | -39.35% | 0.39x | 1.47x | $-96.23 Million |
| 2000 | -16.17% | -29.03% | 0.29x | 1.93x | $-91.89 Million |
| 2001 | 11.55% | 22.36% | 0.29x | 1.76x | $7.03 Million |
| 2002 | 12.62% | 15.45% | 0.36x | 2.25x | $14.96 Million |
| 2003 | -7.18% | -8.30% | 0.56x | 1.55x | $-172.30 Million |
| 2004 | 24.02% | 33.92% | 0.61x | 1.15x | $262.28 Million |
| 2005 | 26.88% | 40.13% | 0.54x | 1.24x | $511.14 Million |
| 2006 | -65.54% | -39.32% | 0.74x | 2.25x | $-1.37 Billion |
| 2007 | 46.69% | 38.19% | 0.72x | 1.69x | $1.27 Billion |
| 2008 | 46.32% | 37.09% | 0.77x | 1.62x | $1.55 Billion |
| 2009 | 41.40% | 37.59% | 0.72x | 1.52x | $2.00 Billion |
| 2010 | 49.48% | 36.50% | 0.69x | 1.98x | $2.31 Billion |
| 2011 | 41.60% | 33.43% | 0.48x | 2.57x | $2.13 Billion |
| 2012 | 27.86% | 26.72% | 0.46x | 2.28x | $1.66 Billion |
| 2013 | 27.04% | 27.45% | 0.50x | 1.99x | $1.94 Billion |
| 2014 | 76.50% | 48.62% | 0.72x | 2.19x | $10.52 Billion |
| 2015 | 94.74% | 55.48% | 0.63x | 2.71x | $16.20 Billion |
| 2016 | 69.73% | 44.43% | 0.53x | 2.94x | $11.56 Billion |
| 2017 | 22.64% | 17.73% | 0.37x | 3.44x | $2.58 Billion |
| 2018 | 25.51% | 24.65% | 0.35x | 2.98x | $3.32 Billion |
| 2019 | 23.91% | 23.99% | 0.36x | 2.74x | $3.13 Billion |
| 2020 | 0.68% | 0.50% | 0.36x | 3.76x | $-1.70 Billion |
| 2021 | 29.55% | 22.80% | 0.40x | 3.23x | $4.12 Billion |
| 2022 | 21.62% | 16.83% | 0.43x | 2.97x | $2.47 Billion |
| 2023 | 24.81% | 20.89% | 0.44x | 2.72x | $3.38 Billion |
| 2024 | 2.48% | 1.67% | 0.49x | 3.05x | $-1.45 Billion |
| 2025 | 37.49% | 28.90% | 0.50x | 2.60x | $6.24 Billion |
Industry Comparison
This section compares Gilead Sciences Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $16,116,025,360
- Average return on equity (ROE) among peers: 24.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gilead Sciences Inc (GILD) | $11.74 Billion | -39.22% | 3.20x | $182.40 Billion |
| AbbVie Inc (ABBV) | $5.10 Billion | 104.16% | 12.89x | $356.49 Billion |
| Amgen Inc (AMGN) | $163.50 Million | 1.04% | 0.18x | $198.99 Billion |
| Amarin Corporation PLC (AMRN) | $-129.19 Million | 0.00% | 0.00x | $252.68 Million |
| AstraZeneca PLC (AZN) | $40.87 Billion | 17.21% | 1.55x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $10.34 Billion | 11.05% | 0.92x | $246.25 Billion |
| Biogen Inc (BIIB) | $239.00 Million | 3.01% | 0.06x | $32.27 Billion |
| Bristol-Myers Squibb Company (BMY) | $10.56 Billion | 20.50% | 1.48x | $126.06 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $1.10 Billion | 36.36% | 0.64x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $76.80 Billion | 23.36% | 1.44x | $574.95 Billion |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatiti… Read more